The societal challenge: health, demographic change and wellbeing, and IMI2. Results from first (2014) calls
|
|
- Esmond Harrell
- 5 years ago
- Views:
Transcription
1 The societal challenge: health, demographic change and wellbeing, and IMI2 Results from first (2014) calls Ruxandra Draghia-Akli, MD, PhD Director Health DG Research and Innovation CLORA 20th April 2015
2 Health in H2020 Excellent science 24bn European Research Council Future and Emerging Technologies Industrial leadership 17bn Marie Skłodowska Curie Research Infrastructures SME instrument Fast Track to Innovation IMI-2 Eureka Eurostars-2 SC1 Health 7.5bn (of 31bn) Collaborative projects LEIT Biotech AAL-2 Financial instruments EDCTP-2
3 SC1 Work Programme Call 'personalising health and care' 34 topics (15 in 2014, 17 in 2015, 2 open in both years) Call for 'co-ordination activities' 16 topics (10 in 2014, 6 in 2015) 1,21 billion
4 SC1 - Analysis of 2014 calls - first coverage overview -
5 Call 'personalising health and care' Topic PHC : Understanding health, ageing and disease: determinants, risk factors and pathways PHC : Health promotion and disease prevention: translating omics into stratified approaches PHC : Evaluating existing screening and prevention programmes PHC : Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens (see also societal challenge 2) PHC : Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis PHC : Development of new diagnostic tools and technologies: in vitro devices, assays and platforms PHC : New therapies for chronic noncommunicable diseases Funded projects Allocated budget million
6 Call 'personalising health and care' PHC /2015: Clinical research on regenerative medicine PHC : Comparing the effectiveness of existing healthcare interventions in the elderly PHC : Advancing active and healthy ageing with ICT: Service robotics within assisted living environments PHC : Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment PHC : Developing and comparing new models for safe and efficient, prevention oriented health and care systems PHC : Self-management of health and disease: citizen engagement and mhealth PHC : Foresight for health policy development and regulation PHC : Advancing bioinformatics to meet biomedical and clinical needs PHC : ehealth interoperability 4 3.8
7 Call 'personalising health and care' (2014) Call PHC-two stage 2014 Number of opened topics 8 Indicative budget available ( ) 303 million Deadline Stage 1 11 March 2014 Stage 1 Number of proposals received 1681 Stage 1 Number of successful proposals 626 Deadline Stage 2 19 August 2014 Stage 2 Number of eligible proposals received 605 Stage 2 Number of funded proposals 62
8 Call 'personalising health and care' (2014) Call PHC-single stage 2014 Number of opened topics 8 Indicative budget available ( ) Deadline 15 April 2014 Number of proposals received 451 Number of funded proposals 41
9 Call 'personalising health and care' (2015) Call PHC-two stage 2015 Number of opened topics 10 Indicative budget available ( ) 306 million Deadline Stage 1 14 October 2014 Stage 1 Number of proposals received 2096 Stage 1 Number of successful proposals 506 Deadline Stage 2 21 April 2015 Stage 2 Number of eligible proposals received evaluation on-going Stage 2 Number of funded proposals evaluation on-going
10 Call 'personalising health and care' (2015) Call PHC-single stage 2015 Number of opened topics 8 Indicative budget available ( ) Deadline 24 February 2015 (RTD) 21 April 2015 (CNECT) Number of proposals received Number of funded proposals 80 (3 topics - RTD) evaluation on-going
11 PHC 1 - Understanding health, ageing and disease: determinants, risk factors and pathways LIFEPATH: Life course biological pathways underlying social differences in healthy ageing Objectives: To understand the mechanisms through which healthy ageing pathways diverge by socio-economic status, including the investigation of lifecourse biological pathways using -omics technologies To examine the consequences of economic recession and of the associated increase in social inequalities on health and biology of ageing To obtain information on healthy ageing at different stages of life, based on the concepts of life-course epidemiology and multi-morbidity To integrate social sciences approaches with biological studies Impact: Understanding the determinants of diverging ageing pathways among individuals belonging to different socio-economic groups Devising innovative Public Health strategies to ensure that healthy ageing is an achievable goal for society as a whole
12 PHC 7 - Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens COMPARE: COllaborative Management Platform for detection and Analyses of (Re-) emerging and foodborne outbreaks in Europe Objectives: 'One serves all' analytical framework + data exchange platform for real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. clinical, epidemiological data) Integrative approach: animal, human and zoonotic pathogens, public + veterinary health, academics and public/veterinary health officials EU contribution to global efforts: Global Microbial Identifier and GloPID-R Integrated risk assessment and risk communication tools To generate actionable information for support of patient diagnosis, treatment, outbreak detection and investigation Linked to scalable and open-source data- and information platform and to existing and future complementary systems, networks and databases such as those used by ECDC, NCBI and EFSA
13 PHC 6, 23 and 31 => novelties for health policy development Putting Iodine Deficiency (ID) on the map in Europe. EUTHYROID will evaluate Iodine Deficiency prevention and monitoring programmes in 24 European countries, and initiate capacity building for harmonized European ID prevention and monitoring programmes. Validating financing/payment models for integrated chronic care (ICC) for multi-morbid patients. SELFIE will develop new models of care and generate empirical evidence of the impact of ICC and on financing/payment schemes Building future scenarios for health policy. EUROHEALTHY will focus on the effect on health inequalities FRESHER will address future burden of non-communicable diseases, collaboration with OECD
14 Type of organisations in signed GA resulting from PHC-2014 calls
15 Countries of origin of coordinators in signed GA resulting from PHC-2014 calls
16 Call for 'co-ordination activities' Activitis in 2014 European Innovation Partnership on Active and Healthy Ageing (EIP-AHA) Funded projects 1 2 Allocated budget million Joint Programming Initiative 'More Years, Better Life's (MYBL) 1 2 Joint Programming Initiative on neurodegenerative diseases (JPND) 1 10 Translational cancer research Systems medicine for clinical needs Rare diseases Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) Global Alliance for chronic diseases (GACD) diabetes 3 10
17 Call for 'co-ordination activities' (2014) Call HCO-single stage 2014 Number of opened topics 11 Indicative budget available ( ) 40 Deadline 15 April 2014 Number of proposals received 49 Number of funded proposals 14
18 Call for 'co-ordination activities' (2015) Call HCO-single stage 2015 Number of opened topics 5 Indicative budget available ( ) 29 Deadline 24 February 2015 Number of proposals received 27 Number of funded proposals evaluation on-going
19 HCO 5 - Global Alliance for chronic diseases (GACD) diabetes Feel4Diabetes: Developing and implementing a community-based intervention to create a more supportive social and physical environment for lifestyle changes to prevent diabetes in vulnerable families across Europe Objectives: To develop, implement and evaluate a community-based intervention aiming to create a more supportive social and physical environment to promote lifestyle and behaviour change to prevent type 2 diabetes Phase I (PRECEDE): identify target population, behaviours and determinants. - review existing type 2 diabetes prevention, policies, legislation - develop a low-cost & applicable in low-resource settings community-based intervention programme Phase II (PROCEED): intervention will be implemented and its process, impact, outcome, cost-effectiveness and scalability will be evaluated Impact: Embedding of the intervention results into new policy and practice
20 Joint Programming Initiative on neurodegenerative diseases (JPND) Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020 Following MS represented: FR (coordinator) AT, BE, DE, DK, ES, IL, IT, LU, NL, PL, PT, RO, SE, SK, UK, Associated countries represented: NO, TR Collaboration partners from Canada Three priority topics have emerged through a consultative process: the identification of genetic, epigenetic and environmental risk and protective factors, the development and maintenance of longitudinal cohorts, the creation of advanced experimental models. These are key questions of equal priority to increase understanding of ND mechanisms that will be addressed
21 Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) Support for international infectious disease preparedness research One project, with key institutions involved GloPID-R-Sec: secretarial support to the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) for 5 years. Staffed by Fondation Mérieux/FR (coordinator) and ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium), hosted by the University of Oxford.
22 Type of organisations in signed GA resulting from HCO-2014 calls
23 Countries of origin of coordinators in signed GA resulting from HCO-2014 calls
24 SME instrument
25 PHC-12: Phase st cut-off - 18 June 208 proposals submitted 24 above thresholds all funded Success rate: 11,5% 4th cut-off 18 March 105 proposals submitted Evaluations on-going 2 nd cut-off - 24 September 152 proposals submitted 21 above thresholds all funded Success rate: 13,8% 3rd cut-off - 17 December 195 proposals submitted 32 above thresholds all funded Success rate: 16,4%
26 Funded SMEs per country phase 1 Country 1 st cut-off 2 nd cut-off 3rd cut-off Total 18 June 24 September 17 December Austria Belgium Germany Denmark Estonia Spain Finland France Hungary Ireland Israel Iceland Italy The Netherlands Norway Serbia Sweden Turkey United Kingdom Total 25* 23* 33* 81*
27 PHC-12: Phase st cut-off 9 October 81 proposals submitted 30 above thresholds 3rd cut-off 18 March 90 proposals submitted Evaluations on-going 10 projects funded Average project size: 3,3 m Success rate: 12,3% 2nd cut-off - 17 December 91 proposals submitted 37 above thresholds 9 projects funded Average project size: 3,3 m Success rate: 10,1%
28 Funded SMEs per country phase 2 Country 1 st cut-off 9 October 2 nd cut-off 17 December Total France Germany Greece Ireland 1-1 Italy Spain 1-1 Sweden The Netherlands United Kingdom Total 10 12* 24*
29 SC1 SME instrument Phase 2 projects - domains covered Dental care Respiratory Heart disease - Myocardial Infarction Cancer (2 projects: cervical, collorectal) Diabetes Arthritis Infections - septic shock Infectious diseases (2 projects: TB, ID self testing platform)
30 SC1 SME instrument Phase 2 projects - examples Validation of clinical performance and pre-commercial development of a novel diagnostic for dental caries assessment Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth Validation of a point-of-care H-FABP test for a rapid exclusion of Acute Myocardial Infarction in patients with cardiac complaints. Validation of PreCursor-M for enhanced Cervical (Pre) Cancer detection Moving to Efficient Diabetes care: Multimode Integrated COmorbidity diagnostics platform
31 Ebola
32 The Research Response to the Ebola Outbreak Apr '14 Jul '14 Oct '14 Jan '15
33 Ebola projects funded by : Horizon 2020 emergency procedure FP7 IMI 2 Vaccines: EbolaVac, VSV-EBOVAC, EBOVAC1, EBOVAC2, EBOMAN, EBODAC Therapeutics: REACTION, Ebola_Tx, IF-Ebola Diagnostics: Mofina, FILODIAG, EbolaMoDRAD Basic research: EVIDENT, Antigone, Predemics Prepareness and Communication: Prepare, Tell Me
34
35 IMI Europe s partnership for health > 5 bn 2.5 bn Partnership bn
36 IMI 1: Budget Breakdown IMI funding 759,185,796 Infectious diseases 14,910,397 Relative effectiveness 18,118,249 Drug kinetics Corporate contribution 20,426,255 Drug delivery 214,136,227 Drug discovery 182,980,698 Brain disorders ,601,855 Sustainable chemistry 37,378,289 Education and training 37,966,496 Lung diseases 116,880,300 Metabolic disorders 49,310,000 Geriatrics 116,287,312 Drug safety 55,930,958 Biological 69,739,527 Inflammatory disorders NATURE MEDICINE NEWS
37 The IMI community 63 projects > 8000 researchers 1100 academic & research teams 493 EFPIA teams 178 SMEs 27 patient org. 17 regulators 61% of projects reported some form of PATIENT INVOLVEMENT REGULATORS ON BOARD OF 12 PROJECTS 50% of projects have REGULATORY AUTHORITIES representatives in Scientific Advisory Boards
38 Number of participations to IMI per country
39 Ongoing IMI projects
40 etox Searchable in a database Publically available toxicology data OH HO O N N N OH Predictive in-silico models Reports from companies
41 StemBANCC 500 Patients 1500 ipscs Diabetes CNS Toxicology Identify phenotypes, Develop assays... Grskovic et al. Nature Reviews, Dec
42 IMI s drug discovery platforms European Lead Factory Focus: identification of new hits European Lead Factory Qualified hit ELF Budget: 196 million europeanleadfactor y.eu Target screenin g Hit-tolead Lead-tocandidat e Preclinic al Phase I Phase II Phase III ND4BB Drug Discovery Platform Lead Clinical candidate Phase 1 ready ENABLE Budget: 101 million nd4bb-enable.eu ENABLE focus: to move promising hits into early clinical development
43 Goals of IMI 2 programme Increase the success rate of clinical trials of new medicines & vaccines Speed up the earlier stages of drug development Develop new treatments for areas of unmet need Develop new biological markers to diagnose diseases and assess treatments Improve the drug development process by creating tools to assess the efficacy, safety and quality of medicines
44 How to get involved Organisations bringing own resources to the project Become an EFPIA partner in research Involved in topic incubation Become an IMI2 Associated Partner Join a pre-established topic prior to Call launch Organisations not bringing own resources to the project Submit a topic idea Form / join a consortium and submit a proposal
45 7 priority themes and enablers Neuro-degeneration Immune-Mediated diseases Metabolic Disorders Infection control Translational safety Medicines Adaptive Pathways to Patients Data generation and exploitation
46 IMI2 Calls IMI2 - Call 1 Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM) Discovery and validation of novel endpoints in dry agerelated macular degeneration and diabetic retinopathy IMI2 Call 1 Number of opened topics 2 Number of proposals received 15 Number of funded proposals 2
47 IMI2 Calls IMI2 - Call 2: Ebola and other filoviral haemorrhagic fevers Vaccine development Phase I, II, and III Manufacturing capability Stability of vaccines during transport and storage Deployment and compliance of vaccination regimens Rapid diagnostic tests IMI2 Call 2 Number of opened topics 5 Number of proposals received 19 Number of funded proposals 8
48 IMI2 Calls IMI2 - Call 3 Remote assessment of disease and relapse (RADAR) - CNS Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification Linking clinical neuropsychiatry and quantative neurobiology The consistency approach to quality control in vaccine manufacture Pertussis vaccination research Knowledge repository to enable patient focused medicine development IMI2 Call 3 Number of opened topics 6 Number of proposals received Number of funded proposals evaluations on-going evaluations on-going
49 IMI2 Calls IMI2 - Call 4 Enabling platform on medicines adaptive pathway to patients (CSA) IMI2 Call 4 Number of opened topics 1 Number of proposals received Number of funded proposals evaluations on-going evaluations on-going
50 Future IMI Calls - Timelines & info Find out more: Call launch: Summer 2015 Disclaimer - All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.
51 Future IMI Calls - Indicative topics 1/2 Patient perspective elicitation on benefits and risks of medicinal products, supplementing benefit risk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle Development of a quantitative system toxicology (QST) platform Diabetic kidney disease (DKD) biomarker idea
52 Future IMI Calls - Indicative topics 2/2 Inflammation and Alzheimer s disease (AD): modulating microglia function focussing on TREM2 and CD33 Understanding the role of amyloid biomarkers in diagnosis, clinical management and treatment of patients with cognitive impairment Evolving models of patient engagement and access for earlier identification of Alzheimer s disease Bringing apolipoprotein E (APOE) biology to validated Alzheimer s disease targets
53 Integration of social sciences and humanities (SSH)
54 PHC : Understanding health, ageing and disease: determinants, risk factors and pathways PHC : Health promotion and disease prevention: translating omics into stratified approaches PHC : Evaluating existing screening and prevention programmes PHC : Comparing the effectiveness of existing healthcare interventions in the elderly 9 Topics flagged as relevant to integrate SSH elements PHC : Developing and comparing new models for safe and efficient, prevention oriented health and care systems PHC : Foresight for health policy development and regulation HCO 5 - Global Alliance for chronic diseases (GACD) diabetes HCO 14 - Bridging the divide in European health research and innovation HCO 15 - Mobilisation and mutual learning action plan
55 Examples of projects (I) Topic HCO 5 - Global Alliance for chronic diseases (GACD) diabetes Topic scope includes: " Provide evidence of a health economics dimension such as cost effectiveness of the proposed intervention and its scalability " Selected project: "Family-based intervention to improve healthy lifestyle and prevent Type 2 Diabetes amongst South Asians with central obesity and prediabetes" (ihealth-t2d) Includes a WP on health economics (124 PM out of 1317 PM - 9,4%) with expertise on health economics, public health
56 Examples of projects (II) Topic PHC 31 - Foresight for health policy development and regulation Topic scope includes: " Proposals should identify key driving forces- (external and internal to the health systems) likely to influence health and wellbeing in Europe and beyond in the future. Proposals should contribute to the understanding of the inter-relationships between these factors; analyse their economic and social impact and suggest alternative policy options to respond to the challenges they pose " Selected project: "Shaping EUROpean policies to promote HEALTH equity" (EURO-HEALTHY) Includes a WP on Socioeconomic, health behaviours and lifestyle determinants of health and wellbeing (82,5 PM out of 457 PM - 18%) with expertise on public health and statistics
57 Examples of projects (III) Topic HCO 15 - Mobilisation and mutual learning action plan Topic scope includes: " MMLs are Coordination and Support Actions (CSA) with at least 10 countries that allow discussion and cooperation between science and society at different stages of the research and innovation process"; "The consortium may also include media, education establishments, science academies, museums, science centres " Selected project: "A stepping stone approach towards the Genetics Clinic of the Future" (GCOF) Includes a WP on public engagement & mutual learning (19 PM out of 117 PM - 16,2%) with expertise on social science, political science
58 Examples of projects (IV) Topic PHC 17 - Comparing the effectiveness of existing healthcare interventions in the elderly Topic scope includes: " A comprehensive array of clinical and safety parameters, as well as health and socio-economic outcomes should be assessed " Topic PHC 23 - Developing and comparing new models for safe and efficient, prevention oriented health and care systems Topic scope includes: " Public health, biomedical, social and behavioural research have provided evidence for new approaches to prevention, primary care and treatment "
59 Stay in touch horizon2020/en/h2020-section/ health-demographic-change-andwellbeing participants/portal
60 Thank you!
Horizon Introduction. Alex Harris Medical Research Council
Horizon 2020 - Introduction Alex Harris Medical Research Council Agenda MRC and Horizon 2020 UK Success Rate (FP7 Health) What is Horizon 2020? The Horizon 2020 Health Challenge NCP support MRC and Horizon
More informationDr.sc. Branka Bernard National Contact Point Member of the Programme Committee
Horizon 2020 - societal challenge 1 Health, demographic change and wellbeing Work Programme 2014-2015 Dr.sc. Branka Bernard National Contact Point Member of the Programme Committee HORIZON 2020 Work Programmes
More informationFuture of diabetes research in the EU- the EC perspectives
Future of diabetes research in the EU- the EC perspectives Dr Karim Berkouk, Deputy Head of Unit DG for Health Directorate European Commission Overview Challenges in diabetes Research in diabetes at EU
More informationNew Horizons for Vaccine R&D&I in Europe
New Horizons for Vaccine R&D&I in Europe Health, Demographic Change and Wellbeing Ruxandra Draghia-Akli MD, PhD Directorate E - Health Research DG - Research & Innovation European Commission Why EU support
More informationGesundheit in Horizont 2020
Wien, 5, Dezember 2013 Gesundheit in Horizont 2020 Gesellschaftliche Herausforderung 1: Gesundheit, demografischer Wandel und Wohlergehen Dr Elmar Nimmesgern GD Forschung und Innovation Europäische Kommission
More informationWhat EU research policy can do for conditions such as chronic pain?
The EU Framework Programme for Research and Innovation HORIZON 2020 What EU research policy can do for conditions such as chronic pain? K Berkouk, PhD Deputy Head of Unit, Non-communicable diseases and
More informationThe European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing
The European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing Sasha Hugentobler National Contact Point Health Euresearch Head Office phone +41 31 380 60
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationMaking dementia a European priority
Making dementia a European priority Glasgow 1 June 2015 Jean Georges, Executive Director Alzheimer Europe 36 associations in 31 countries 2 Paris Declaration Adopted by Annual General Meeting in Paris
More informationThe Innovative Medicines Initiative: an engine for therapeutic innovation
The Innovative Medicines Initiative: an engine for therapeutic innovation Michel Goldman 26.11.2014 Brussels Bringing health-related life science and technology sectors into IMI2 The pillars of innovation
More informationDEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH
DEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH Brussels, 19 March 2015 Michael Hübel Programme Management and Diseases Directorate-General for Health and Food Safety European Commission
More informationThe EU strategy in Horizon2020 to fight poverty related diseases
Meeting on EDCTP2 French Ministry of Education, Science and Innovation, Paris 30 June 2017 The EU strategy in Horizon2020 to fight poverty related diseases Line Matthiessen Acting Director Health Directorate
More informationJoint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference
More informationEU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014
EU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014 EU Horizon 2020 for 2014-2020 In current prices nearly 80 billion; in constant prices
More informationNon communicable diseases
Non communicable diseases Information Day, Brussels 8 July 2016 K. Berkouk, PhD Deputy Head of Unit, Non-Communicable Diseases and the challenge of Healthy Ageing, European Commission NCD A Global challenge
More informationJoint Programming Initiative on Neurodegenerative Diseases. Prof. Philippe Amouyel Chair, JPND Management Board
Joint Programming Initiative on Neurodegenerative Diseases Prof. Philippe Amouyel Chair, JPND Management Board Cases / 100 Alzheimer s disease in Europe 40 Number of cases Societal costs ( ) 2010 6,000,000
More information14 December :00 CET
Webinar IMI2 Call 13 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches 14 December 2017 15:00 CET Agenda How to use
More informationFrom IMI to IMI2. Hugh Laverty Senior Scientific Project Manager
From IMI to IMI2 Hugh Laverty Senior Scientific Project Manager FitForHealth June 2014 Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in
More informationMental Health. Patrizia Tosetti, PhD Unit F2 Medical Research DG Research and Innovation
European efforts in Mental Health research Patrizia Tosetti, PhD Unit F2 Medical Research DG Research and Innovation European Commission Conference on Psychotherapy in Europe EP, Brussels 9 February 2012
More informationNORDIC CONFERENCE ON RARE DISEASES
www.eurordis.org NORDIC CONFERENCE ON RARE DISEASES 31 May 2012, Reykjavik, Iceland www.eurordis.org RARE DISEASES IN EUROPE Terkel ANDERSEN President of EURORDIS European Organisation for Rare Diseases
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22.12.2008 COM(2008) 882 final REPORT FROM THE COMMISSION TO THE COUNCIL, THE EUROPEAN PARLIAMENT, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE
More informationMonthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
More informationEU support to hepatitis research. Anna Lönnroth Sjödén Health Research DG Research - European Commission
EU support to hepatitis research Anna Lönnroth Sjödén Health Research DG Research - European Commission Hepatitis B and C Summit, Brussels, 15 October 2010 1 Main Objectives: to improve quality of life
More informationExtrapolation and potential impact of IPHS deployment in Europe
SIMPHS2 Validation Workshop Brussels, 31 Jan 2012 1 SIMPHS2 Validation Workshop Extrapolation and potential impact of IPHS deployment in Europe JRC IPTS IS Unit Ioannis Maghiros, Fabienne Abadie, Maria
More informationUpdates from the European Centre for Disease Prevention and Control
Updates from the European Centre for Disease Prevention and Control AIRA 2018 National Meeting, Salt Lake City Global Perspectives Plenary session Tarik Derrough Senior Expert Vaccine Preventable Diseases
More informationEU-Funded Research on EMF and Health'
EU-Funded Research on EMF and Health' Dr Tuomo Karjalainen Research Programme Officer in Environment and Health Research and Innovation Directorate-General Health Directorate Athens, 28 March 2014 Environment
More informationMoving towards 2020 priorities for Public Health for the years Health and Consumers
Moving towards 2020 priorities for Public Health for the years 2013-20 Health in the MFF 2014-2020 Commission proposal for the Health for Growth Programme 2014-2020 http://ec.europa.eu/health/programme/policy/index_en.htm
More informationEuropean Collaboration on Dementia. Luxembourg, 13 December 2006
European Collaboration on Dementia Luxembourg, 13 December 2006 2005 Call for projects Special attention has also to be given to information and definition of indicators on neurodegenerative, neurodevelopment,
More informationINTRODUCTION TO THE REMOTE ASSESSMENT OF DISEASE AND RELAPSE (RADAR) PROGRAMME
INTRODUCTION TO THE REMOTE ASSESSMENT OF DISEASE AND RELAPSE (RADAR) PROGRAMME All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls
More informationTowards Integrated Syndromic Surveillance in Europe?
Towards Integrated Syndromic Surveillance in Europe? Duncan Cooper - Born in Bradford Research Study, UK Triple-S partners including Anette Hulth, Alexandra Ziemann, Jean-Babtiste Perrin, Mark Kanieff,
More informationNew funding opportunities in the Health area. and support at UiB
New funding opportunities in the Health area and support at UiB Societal Challenge 1 Work Programme Health, Demographic Change and Wellbeing Corina Guder Research Advisor FA, BOA-Team UNIVERSITETET I BERGEN
More informationPerspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU
Perspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU N. Safrany European Commission Pr. A. Nicoll ECDC 2 nd WHO GAP mtg 12-14 July 2011 Background
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationEuropean Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
More informationCYPRUS PRESIDENCY OF THE COUNCIL OF THE EU
CYPRUS PRESIDENCY OF THE COUNCIL OF THE EU July December 2012 Research Symposium on Digestive and Liver Diseases Brussels, 18 September 2012 Dr Myrto Azina- Chronides Ministry of Health Cyprus Digestive
More informationPalliative nursing care of children and young people across Europe
Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)
More information1. The Working Party on Public Health discussed and agreed the draft Council conclusions as set out in the Annex.
Council of the European Union Brussels, 26 November 2015 (OR. en) 14395/15 SAN 391 NOTE From: To: Subject: General Secretariat of the Council Permanent Representatives Committee/Council Employment, Social
More informationEmerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018
Emerging Risks Mapping of Activities in Member States 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018 BACKGROUND 67 th Advisory Forum Meeting, Utrecht, The Netherlands, 6 February
More informationCancer Research in the EU Framework Programmes for RTD
Cancer Research in the EU Framework Programmes for RTD Action against cancer: European platform Maria Vidal, MD, PhD Deputy Head of Unit Medical and public health research Health Directorate DG Research
More informationA2 Action Group on Personalized Health Management and Falls Prevention
1 Authors Nick Guldemond, AG A2 Coordination Team Chair Maite Ferrando, AG A2 Promoter 2015-2016 (CSA PROEIPAHA) Valentina Tageo, AG A2 Secretariat Support Service 2015-2016 (CSA PROEIPAHA) With many thanks
More informationHealth and. Consumers
www.openprogram.eu EU action on obesity Obesity Prevention through European Network Closing event Amsterdam 25 November 2016 Attila Balogh Health determinants and inequalities European Commission Directorate-General
More informationHorizon Tailored screening as a research challenge. Mireille Broeders 30 January 2014, Bologna
Horizon 2020 Tailored screening as a research challenge Mireille Broeders 30 January 2014, Bologna Dept for Health Evidence, Radboudumc & National Expert and Training Centre for Breast Cancer Screening,
More informationDiscovery and validation of novel. Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies
Discovery and validation of novel Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies Dr. Angela Wittelsberger, IMI IMI webinar 29.04.2016 Today s webinar Will cover all aspects of the
More informationThe cancer burden in the European Union and the European Region: the current situation and a way forward
The cancer burden in the European Union and the European Region: the current situation and a way forward Presented by Zsuzsanna Jakab WHO Regional Director for Europe Informal Meeting of Health Ministers
More informationA pan European Dementia Strategy
A pan European Dementia Strategy Luxembourg 13 June 2017 Vanessa Challinor, Policy Officer @vanessachall Agenda Alzheimer Europe Campaign to recognise dementia as policy and research priority National
More informationPersonal Health Systems. Loukianos Gatzoulis DG Information Society & Media European Commission
Personal Health Systems Loukianos Gatzoulis DG Information Society & Media European Commission ICT WP preparation Consultation with stakeholders is key: 1) Through dedicated events Consultation Workshops
More informationPREVENTION FIRST : VACCINATION AT THE HEART OF PUBLIC HEALTH
PREVENTION FIRST : VACCINATION AT THE HEART OF PUBLIC HEALTH Vaccines Europe calls for EU leadership to develop a comprehensive EU vaccination strategy aimed to support Member States in implementing effective
More informationInequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
More informationTHE GLOBAL HEALTH SECURITY AGENDA. We have to change our mindsets and start thinking about biological threats as the security threats that they are.
THE GLOBAL HEALTH SECURITY AGENDA We have to change our mindsets and start thinking about biological threats as the security threats that they are. President Barack Obama September 26, 2014 1 Global Health
More informationBrain research supported by the European Union
Brain research supported by the European Union Lara Passante, PhD Health Directorate Directorate-General for Research & European Commission FENS Featured Regional Meeting 11-14 Septembre 2013 Prague Neuroscience:
More informationPain and Palliative care in the European Commission s Framework Programmes. European Commission Research DG Dr. Elengo Manoussaki
Pain and Palliative care in the European Commission s Framework Programmes European Commission Research DG Dr. Elengo Manoussaki European Parliament resolution on combating cancer in the enlarged EU Calls
More information5 th Islamic Conference of Health Ministers. Resolution. Istanbul, Turkey November 2015 (5-7 Safar 1437H)
5 th Islamic Conference of Health Ministers Resolution Istanbul, Turkey 17-19 November 2015 (5-7 Safar 1437H) Draft Resolution No. 2/5-ICHM On Healthy Life Style, Prevention and Control of Communicable
More information7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities
7th Mena Influenza Stakeholders Meeting WHO Influenza Strategy Development and Vaccine-related Research Priorities Wenqing Zhang 9 10 September 2017 Riga, Latvia 1 Seasonal influenza 1 billion cases yearly
More informationRD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS
RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS Stakeholder Group Interest in RD-Action Dissemination purpose Channels of Dissemination (WHO) (WHY) (WHY) (HOW) Partners of RD-Action & members
More informationCouncil of the European Union Brussels, 28 October 2015 (OR. en)
Conseil UE Council of the European Union Brussels, 28 October 2015 (OR. en) PUBLIC 13261/15 LIMITE SAN 347 NOTE From: To: Subject: General Secretariat of the Council Working Party on Public Health Draft
More informationImproving surveillance and early detection of outbreaks. Frank M. Aarestrup
Improving surveillance and early detection of outbreaks Frank M. Aarestrup www.compare-europe.eu www.genomicepidemiology.org INFECTIOUS DISEASES Direct cause of 22% of all global deaths (15 million), huge
More informationOverview of European Consumption Databases
FEDERAL INSTITUTE FOR RISK ASSESSMENT Overview of European Consumption Databases Katrin Büsch Workshop Food Consumption Data and Dietary Exposure in the European Union, 15-16 May 2008, Berlin Introduction
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationManuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal Public Health Public health is the science and art of preventing disease, prolonging
More informationPOSITION PAPER PALLIATIVE CARE, PEDIATRIC PALLIATIVE CARE AND PAIN THERAPY: HUMANIZATION OF CARE
POSITION PAPER 1 PALLIATIVE CARE, PEDIATRIC PALLIATIVE CARE AND PAIN THERAPY: HUMANIZATION OF CARE GROUP LEADER: Basilicata Region OTHER PARTNERS: Calabria; Campania; Lazio; Marche; Piemonte; Prov. Aut.
More informationFamilies across Europe following a healthy Lifestyle FOR Diabetes prevention : Feel4Diabetes
Families across Europe following a healthy Lifestyle FOR Diabetes prevention : Feel4Diabetes Yannis Manios Harokopio Associate University Professor Department of Nutrition and Dietetics School of Health
More informationCHRODIS Kick-off. Communication and Dissemination. Cristina Chiotan / Anna Gallinat Public Health Coordinator / Communications Assistant
CHRODIS Kick-off Communication and Dissemination Cristina Chiotan / Anna Gallinat Public Health Coordinator / Communications Assistant EuroHealthNet The European Partnership for improving health, equity
More informationEUVAC.NET A surveillance network for vaccine-preventable diseases
EUVAC.NET A surveillance network for vaccine-preventable diseases Mark Muscat EUVAC.NET Co-ordinator Department of Epidemiology Statens Serum Institut Denmark Email: mmc@ssi.dk Viral Hepatitis Prevention
More informationIARC A UNIQUE AGENCY. Cancer research for cancer prevention
IARC A UNIQUE AGENCY Cancer research for cancer prevention Director s message IARC is a unique organization. For the past 50 years, the Agency has been making important contributions to the global fight
More informationWhat s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey
What s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey Liisa Valsta Data Collection and Exposure Unit What s s on the menu in Europe? Background Attempts
More informationA progress report on the Joint Programming Initiative
A progress report on the Joint Programming Initiative In April 2010, Alzheimer Europe talked about the aims of the Joint Programming Initiative on Neurodegenerative Diseases (JPND) with the Initiative
More informationPriorities for achieving Millennium Development Goals (MDGs) 4 and 5 in the European Region
Priorities for achieving Millennium Development Goals (MDGs) 4 and 5 in the European Region Zsuzsanna Jakab WHO Regional Director for Europe A big challenge Globally every year 7.6 million children die
More informationPREPARE. Herman Goossens, Coordinator. Panel discussion, GLoPID-R meeting, Sao Paulo, Brazil December 1, 2016
PREPARE Herman Goossens, Coordinator Panel discussion, GLoPID-R meeting, Sao Paulo, Brazil December 1, 2016 PREPARE is funded by the European Commission under grant number 602525 Agenda Network structure
More informationChanging the prevention paradigm for the future what Europe can do
November 3rd, 2014 Honorable Beatrice Lorenzin, Minister of Health of Italy Italian Presidency of the EU Council Conference/Meeting The State of Health of Vaccination in the EU: where do we stand, where
More information3.1 Publishable summary
3.1 Publishable summary PROJECT CONTEXT AND OBJECTIVES Type 2 diabetes, formerly known as non insulin dependent diabetes (NIDDM), is one of the fastest growing chronic diseases worldwide. This is primarily
More informationNew trends in harm reduction in Europe: progress made challenges ahead
New trends in harm reduction in Europe: progress made challenges ahead Dagmar Hedrich, Alessandro Pirona, EMCDDA 2 nd European Harm Reduction Conference, 7-9 May 2014, Basel Session 4: Changes in harm
More informationThe Identification of Food Safety Priorities using the Delphi Technique
The Identification of Food Safety Priorities using the Delphi Technique Gene Rowe & Fergus Bolger, GRE 58th Advisory Forum Meeting, Luxembourg, 8-9 December 2015 EU RISK ASSESSMENT AGENDA (RAA) where priorities
More information2018 INFUSE CALL FOR INNOVATION
2018 INFUSE CALL FOR INNOVATION Leveraging digital technologies for registration, identification, digital record-keeping and follow-up to ensure healthier futures Imagine a future in which all children
More informationSpreading Excellence and Widening Participation
Spreading Excellence and Widening Participation Dr G Ambroziewicz Ankara, 27/02/2017 Research and Background Disparities in research and innovation performance: barrier to competitiveness, growth and jobs
More informationPublic Health Challenges. Identified by Public Health England
Public Health Challenges Identified by Public Health England Environmental Public Health 1. Environmental Change and Health What environmental public health interventions can be identified and developed
More informationWhere we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
More informationReal world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform
Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform Catherine Reed, Lilly on behalf of ROADMAP consortium 3 rd Nordic conference on Real World Data, 28-29 November
More informationInternationalisation of green SMEs
Eva Revilla Internationalisation of green SMEs DG Internal Market, Industry, Entrepreneurship and SMEs European Commission 27/05/2015 Internationalisation of green SMEs Where are we? 91% of SMEs sell their
More informationThe health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
More informationNIHR Supporting collaboration in life sciences research
NIHR Supporting collaboration in life sciences research Dr Matt Hallsworth - Head of External Relations, NIHR Office for Clinical Research Infrastructure (NOCRI) Research funders build capabilities and
More informationEuropean status report on alcohol and health Leadership, awareness and commitment
European status report on alcohol and health 2014 Leadership, awareness and commitment Leadership, awareness and commitment Background Strong leadership from national and local governments is essential
More informationEU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017
EU Market Situation for Poultry Committee for the Common Organisation of the Agricultural Markets 2 April 217 -9.% -11.% -5.% -.1% -.7% -2.2% 3.% 1.7% 1.2%.8%.6%.%.%.% 7.9% 7.% 6.4% 6.2% 6.% 5.5% 5.3%
More informationHighlighting in the WHO European Region: Summary. No. 21(February 2012)
No. 21(February 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationEU funding of animal health research
EU funding of animal health research Jean-Charles CAVITTE Research Policy Officer Research and Innovation Unit European Commission DG Agriculture and Rural Development The presentation shall neither be
More informationThe challenge of obesity in the WHO European Region
Fact sheet EURO/13/05 Copenhagen, Bucharest, 12 September 2005 The challenge of obesity in the WHO European Region Obesity poses one of the greatest public health challenges for the 21st century, with
More informationTowards tailored and targeted asthma self-management using mobile technologies
Towards tailored and targeted asthma self-management using mobile technologies Funded by the European Union Asthma: the problem Asthma is a lifelong chronic disease caused by inflammation of the airways,
More informationCardiovascular Disease and Diabetes Policies for Better Health and Quality of Care
Policy Brief Cardiovascular Disease and Diabetes Policies for Better Health and Quality of Care June 2015 Directorate for Employment, Labour and Social Affairs Over the last few decades, mortality from
More informationAnnual epidemiological report 2014 food- and waterborne diseases and zoonoses
Annual epidemiological report 2014 food- and waterborne diseases and zoonoses SURVEILLANCE REPORT Salmonellosis Salmonellosis is the second most commonly reported gastrointestinal infection and an important
More informationFuture of Diabetes Research in Europe JDRF Perspective
Future of Diabetes Research in Europe JDRF Perspective IMI-JDRF Diabetes Patient Meeting 20 May 2014 Brussels, Belgium Olivier ARNAUD, Pharm D JDRF European Research Director oarnaud@jdrf.org Future of
More informationEU Health Programme: working together to improve public health in Europe
EU HEALTH PROGRAMME EU Health Programme: working together to improve public health in Europe A selection of Public Health Projects with an important impact for EU Member States EUROPEAN COMMISSION The
More informationrare diseases research through National Plans and Strategies
Recommendations to support rare diseases research through National Plans and Strategies Dr Domenica Taruscio EUROPLAN Coordinator Director of the Italian Centre for Rare Diseases, Italian National Institute
More informationPROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL, ECONOMIC, SOCIAL AND CULTURAL RIGHTS, INCLUDING THE RIGHT TO DEVELOPMENT
UNITED NATIONS A General Assembly Distr. LIMITED A/HRC/11/L.16 16 June 2009 Original: ENGLISH HUMAN RIGHTS COUNCIL Eleventh session Agenda item 3 PROMOTION AND PROTECTION OF ALL HUMAN RIGHTS, CIVIL, POLITICAL,
More informationThe Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert
Albania. Algeria. Armenia. Austria. Belarus. Belgium. Bosnia & Herzegovina. Bulgaria. Croatia. Cyprus. Czech Republic Denmark. Egypt. Estonia. Finland. Former Yugoslav Republic of Macedonia. France. Georgia.
More informationSeasonal influenza vaccination Recommendations & Reality
Seasonal influenza vaccination Recommendations & Reality World Vaccine Congress, 16-18 October 2012, Lyon, France Caroline Brown Influenza and other Respiratory Pathogens WHO Regional Office for Europe
More informationTowards a Sustainable Global Infrastructure for Medical Countermeasures
Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from
More informationJohns Hopkins individualized Health Initiative
Johns Hopkins individualized Health Initiative Hopkins inhealth Scott L. Zeger Professor of Biostatistics Vice Provost for Research Chair, Johns Hopkins Individualized Health Steering Committee May 16,
More information